ZEPATIER (elbasvir grazoprevir), fixed combination of direct-acting antivirals
Reason for request
Minor clinical added value, like other direct-acting antivirals (HARVONI, DAKLINZA, OLYSIO, VIEKIRAX, EXVIERA), in the treatment of genotype 1 and 4 chronic hepatitis C.
- ZEPATIER has Marketing Authorisation in the treatment of chronic hepatitis C in adults infected with genotype 1 and 4 hepatitis C virus (HCV).
- It represents minor clinical added value in treatment, given:
- its substantial virological efficacy in patients infected with genotype 1 and 4 HCV with a treatment duration of 12 to 16 weeks (± ribavirin) for patients with or without compensated cirrhosis (Child-Pugh A only),
- the demonstration of efficacy superior to sofosbuvir + peg-interferon/ribavirin triple therapy (comparator that is no longer optimal), with an extent of effect comparable to the alternatives currently recommended,
- the demonstration of significant efficacy in specific populations, such as renal failure or dialysis patients, for whom the alternatives are limited and insufficiently evaluated,
- its satisfactory safety profile,
- its significant risk of developing resistance in the case of treatment failure,
- the absence of comparison with the other direct-acting antiviral combinations available, such as sofosbuvir + NS5A inhibitor combinations which most often allow a shorter treatment duration (8-12 weeks) without addition of ribavirin.
Clinical Benefit
Substantial |
- |
Unspecified |
Clinical Added Value
minor |
- |
Therapeutic use
- |